Cambridge, Massachusetts, United States
I am an experienced, passionate leader in clinical development, program leadership, and medical affairs, with expertise in oncology, hematology and bone diseases. At Takeda, I oversee our oncology R&D strategy and development portfolio as Head of the Oncology Therapeutic Business Unit. Prior to Takeda, I served as the Chief Medical Officer at CRISPR Therapeutics where I led a cross-functional team overseeing end-to-end development of clinical programs spanning hematology, oncology, diabetes and cardiovascular disease. Before joining the industry, I was a practicing physician, completing my internal medicine residency at Baylor College of Medicine and a Hematology/Oncology Fellowship at the University of Texas MD Anderson Cancer Center. Throughout my career, I have overseen the development of numerous medicines, as well as the implementation of strategic partnerships with academic institutions, key opinion leaders, regulatory agencies and biopharmaceutical collaborators to facilitate successful execution of clinical trials. As the oncology landscape continues to evolve, I focus on leading my teams with a steadfast commitment to advancing new treatment options and supporting people affected by cancer. Follow along to learn more of my work.
Responsible for Takeda’s oncology R&D strategy and development portfolio, advancing medicines for hematologic, gastrointestinal and thoracic cancers.
Led a diverse and cross-functional team, spanning Development, Regulatory, Safety, Medical Affairs, Clinical Operations, Clinical Pharmacology, Medical Writing, Data Management, Biostatistics, and Programming. Guided the end-to-end development of innovative therapies addressing oncology, hemoglobinopathies, diabetes, and cardiovascular diseases. Partnered with Vertex on development of exa-cel, leading to the first approval of a CRISPR-gene editing product for the treatment of severe sickle cell disease and for transfusion-dependent beta thalassemia.